Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96BR1

UPID:
SGK3_HUMAN

ALTERNATIVE NAMES:
Cytokine-independent survival kinase; Serum/glucocorticoid-regulated kinase 3; Serum/glucocorticoid-regulated kinase-like

ALTERNATIVE UPACC:
Q96BR1; A8K5W3; B3KQC2; Q9P1Q7; Q9UKG5

BACKGROUND:
The Serine/threonine-protein kinase Sgk3, with alternative names such as Cytokine-independent survival kinase and Serum/glucocorticoid-regulated kinase 3, is integral to regulating ion channels, membrane transporters, and cellular dynamics. It enhances the activity of Na(+), K(+), and Ca(2+) channels, among others, playing a key role in cell physiology.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine/threonine-protein kinase Sgk3 unveils potential avenues for therapeutic intervention. Its critical role in cellular signaling pathways offers promising opportunities for developing novel treatments targeting diseases linked to cell growth and migration.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.